ICH-Q10: A Recipe for the Product Life Cycle - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ICH-Q10: A Recipe for the Product Life Cycle
The draft guidance ICH Q10 for pharmaceutical quality systems is part of the ongoing move to a science- and risk-based approach in manufacturing.


Pharmaceutical Technology


"Q10 covers the life cycle from development to the termination of the product," explains Famulare. "All of the elements in ICH Q8 and ICH Q9 fall under this quality-system umbrella, which needs to be threaded and implemented throughout the life cycle." For example, the quality system provides firms the ability to mange within the design space as described in ICH Q8. The document is consistent with the elements of ICH Q7 applying to active pharmaceutical ingredients, notes Famulare.


The players in the International Conference on Harmonization
"Q10 pulls all of these ideas together into process and product realization over the life cycle of the product. It provides for the utilization of knowledge over the commercial life cycle to serve as a means of continual improvement and back to development where this knowledge can be used for future development," says Famulare.

The systems approach presented in ICH Q10 has a common theme with ICH Q8 and ICH Q9 in that it is centered on a science- and risk-based model, explains Jason Kamm, managing consultant at Tunnell Consulting (King of Prussia, PA).

"The ICH Q8 guidance on product development helps define the activities a company must show to demonstrate they understand their manufacturing processes and that proper controls are in place—the basic elements of the science-based approach," says Kamm. "Changes can therefore be made autonomously without previous approval of a regulating agency (inside the design space) based on demonstrated knowledge or understanding of the product or process. Since product development is an element of the product life cycle, ICH Q10's linkage to ICH Q8, which establishes the building blocks of the science-based approach, is clear."

ICH Q10 also complements the quality risk-management concepts embodied in ICH Q9. "The ICH Q9 guidance on the risk-based approach helps define the activities a company may take based on the use of risk management," says Kamm. These activities relate to items such as changes, release tests, and process controls and monitoring. "Throughout the product life cycle, whenever decisions are made, risk must first be identified, and systems must be in place to adequately control them," he says. "This allows for a departure from the mechanical nature of compliance in the past. Activities can be prioritized based on risk; more time is spent on areas of high risk, and less time is spent on areas of lower risk."

Kamm explains the main moving parts of a quality system include the handling of deviations, CAPA, release systems, and process monitoring and controls. These components rely on two concepts that are a common theme throughout ICH Q10: continuous improvement and the management of change resulting from these improvements. "ICH Q10 makes it clear that these elements apply not only to the product throughout its life cycle, but also to the quality system itself."

In addition to these components, ICH Q10 also defines the product life cycle to include product development, technology transfer, manufacturing and product discontinuation. "Continuous improvement involves elements such as cost savings, streamlining, and elimination of waste," says Kamm. "In addition, and perhaps more critically, continuous improvement allows for deeper process understanding throughout the product life cycle."

ICH Q10 and quality systems

The underlying principles of the pharmaceutical quality system in ICH Q10 are consistent with the effort by FDA when issuing its 2006 guidance on quality systems (5). That guidance was intended to help manufacturers implement modern quality systems and risk-management approaches to meet the requirements of the agency's CGMP regulations (5).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here